See inside every stock. Pro
S&P 5007,723▲ 0.60%Nasdaq26,478▲ 1.18%Dow Jones52,378▲ 0.03%Nasdaq 10029,651▲ 1.29%VIX17.52▼ 4.73%US Dollar102.35▲ 0.39%Gold spot4,006▲ 0.30%WTI101.57▲ 1.67%
Hong Kong Stock Exchange · Hong Kong · Updated after 27 Oct 2026 close

Sichuan Kelun-Biotech

6990 · Hong Kong Stock Exchange · prices in HKD
HKD 453.20▼ -27.00 (5.62%)
Research report

About Sichuan Kelun-Biotech

Sichuan Kelun-Biotech is a biopharmaceutical company based in China that researches, develops and commercialises medicines. Its work centres on innovative treatments in areas such as oncology and other serious diseases, including antibody-drug conjugates and small-molecule drugs. The company serves patients and healthcare providers through its own product portfolio and through partnerships with pharmaceutical companies that license its drug candidates for development and sale in markets outside China.

The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 6990, and the price on this page is in Hong Kong dollars (HKD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

74/ 100
Market X-Ray · price-based
Strong price profile
Ranks #233 of 2619 on the Hong Kong Stock Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Hong Kong yet.
TrendStrong
79/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average-1.1%
From 52-week high-16.5%
MomentumFair
60/100
Typical recent returns for this exchange.
See the numbers →
3-month return-11.7%
6-month return-2.9%
12-month, skipping last month8.7%
Stability (higher is calmer)Fair
70/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)51.6%
Worst drawdown, 1 year (smaller is calmer)-28.8%
LiquidityStrong
96/100
Trades actively.
See the numbers →
Avg daily value traded311.12M HKD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Hong Kong when fundamentals data for this market is added. All Hong Kong stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
339.60 – 562.50
Price is 51% of the way up
Returns
−11.7% 3m · +5.5% 1y
Price returns, dividends not included
RSI (14)
46
Neutral zone

Price chart

52-wk range 339.60 – 562.50 Daily closes, split-adjusted

Signals

50-day average481.28
200-day average458.26
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)26.82

Technical summary

Daily
Strongly bearish
1 bullish · 4 neutral · 11 bearish
Weekly
Bearish
2 bullish · 1 neutral · 7 bearish
Monthly
Bullish
4 bullish · 1 neutral · 2 bearish
Moving averages (daily)
SMA 10456.0Bearish
EMA 10459.9Bearish
SMA 20460.2Bearish
EMA 20462.2Bearish
SMA 50481.3Bearish
EMA 50472.2Bearish
SMA 100476.1Bearish
EMA 100472.6Bearish
SMA 200458.3Bearish
EMA 200457.5Bearish
Oscillators (daily)
RSI (14)46.26Neutral
MACD (12, 26)-4.81Bearish
Momentum (12)1.66Bullish
Stochastic %K (14)33.05Neutral
Williams %R (14)-66.95Neutral
CCI (20)-2.91Neutral
Pivot points (classic, last session)
S3
393.0
S2
418.8
S1
436.0
Pivot
461.8
R1
479.0
R2
504.8
R3
522.0
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in HKD. Educational only, not financial advice.